Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

https://www.nejm.org/doi/full/10.1056/NEJMoa2012410

Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.

Tags: